Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- BUSINESS NEWS IN BRIEF
July 27, 2009
- Patients, Doctors Remain Calm Despite EASD Reports on Lantus: sanofi-aventis
July 27, 2009
- Cravit No. 1 on HP Market, No. 2 on GP Market: Rep Track Survey
July 27, 2009
- Merck Serono Aims at Becoming No. 1 in Reproductive Health, Metabolic Oncology
July 27, 2009
- Hisamitsu to Acquire Noven Pharm. to Strengthen US Business Platform
July 27, 2009
- Immunology/Inflammation MTPC's 3rd Top-Priority Field
July 27, 2009
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
July 27, 2009
- Nat'l Univ. Hospitals Apprehensive of Negative Effects of Use of Generics on Their Research
July 27, 2009
- R&D NEWS IN BRIEF
July 27, 2009
- Zeria Launches Additional OTC Versions of Acinon
July 27, 2009
- Korosho to Build Up Network of Global Clinical Research Centers
July 27, 2009
- R&D NEWS IN BRIEF
July 20, 2009
- Japan Biotechnology Conference Kicked Off by 20 Biotech Firms
July 20, 2009
- ASCO 2009 Highlight Seminar by the Matson Jack Group
July 20, 2009
- Pfizer Discontinues PIII Trial of Sutent in Metastatic CRC
July 20, 2009
- GENERICS NEWS IN BRIEF
July 20, 2009
- Survey on Generics of Anticancer Drugs Shows Gaps between Generic Firms and Healthcare Professionals
July 20, 2009
- Anplag to Be Major Target for Generic NHI Price Listing in November
July 20, 2009
- REGULATORY NEWS IN BRIEF
July 20, 2009
- Pfizer Offers Reduced Working-Hour Program for MRs
July 20, 2009
ページ
Japan’s FY2026 drug price revision, officially announced on March 5, has landed poorly with the pharmaceutical industry — and the…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…